Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein
about
The cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for traumatic brain injuryTHE ROLE OF CYSTEINE PROTEASE IN ALZHEIMER DISEASECysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitorsCathepsin B is a New Drug Target for Traumatic Brain Injury Therapeutics: Evidence for E64d as a Promising Lead Drug CandidateInflammasomes: mechanism of action, role in disease, and therapeuticsBrain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeuticThe cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activityGenetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor proteinDeletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence.Running-Induced Systemic Cathepsin B Secretion Is Associated with Memory FunctionThe protein architecture of human secretory vesicles reveals differential regulation of signaling molecule secretion by protein kinasesThe NALP3 inflammasome is involved in the innate immune response to amyloid-betaIsoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases.Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease.Computational analysis of the cathepsin B inhibitors activities through LR-MMPBSA binding affinity calculation based on docked complex.The identification, characterization and optimization of small molecule probes of cysteine proteases: experiences of the Penn Center for Molecular Discovery with cathepsin B and cathepsin L.QSAR models for predicting cathepsin B inhibition by small molecules--continuous and binary QSAR models to classify cathepsin B inhibition activities of small molecules.Inflammasomes: molecular regulation and implications for metabolic and cognitive diseasesAn overview of APP processing enzymes and products.Multi-conformation 3D QSAR study of benzenesulfonyl-pyrazol-ester compounds and their analogs as cathepsin B inhibitors.Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis.Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication.Inflammasomes as therapeutic targets for Alzheimer's disease.Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathologyCysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's diseaseA missense variant in CST3 exerts a recessive effect on susceptibility to age-related macular degeneration resembling its association with Alzheimer's disease.Interacting partners of macrophage-secreted cathepsin B contribute to HIV-induced neuronal apoptosis.Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's diseaseGenetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration.Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.Gene therapy in Alzheimer's disease - potential for disease modificationCell biology, regulation and inhibition of beta-secretase (BACE-1).Apoptosis and in vitro Alzheimer disease neuronal models.The marine cyanobacterial metabolite gallinamide A is a potent and selective inhibitor of human cathepsin L.Alzheimer's disease and the amyloid-beta peptide.Autophagic/lysosomal dysfunction in Alzheimer's disease.
P2860
Q24601910-9433CE68-95B7-442F-8D3D-7CF82CC7942DQ26740104-6533C151-6E92-42C6-B154-6F2029FE80E0Q26771736-DDDE857F-8250-4B34-84CD-AAC9A663C664Q26782938-7279CE2F-1448-4319-9E5C-190A66195424Q27001186-F9571368-FC17-481C-A580-CE75AC0C69C6Q28235248-CBCD85F9-3D0E-454C-9602-641CD31D5D30Q28238581-5E1A6E05-169C-4D9B-A723-7DFC395CBFA6Q28247574-C11115F1-09B5-403C-969B-F3029E01A6DEQ28259920-4D6E8B21-3998-47A8-88D6-A21072E86D03Q28276622-4BA5AE4A-44B1-4F41-ABC8-1FF9A64FF72AQ28482305-6F3C2074-16C5-4D44-91B6-D7ED62C25267Q29615595-6EE580B4-1AC2-4771-A37D-CEF29EF8416EQ30319326-E197DF99-DD34-41ED-B78C-6A32B6251168Q30490690-26653058-35A3-4713-A482-ABC8C7121F7FQ33412456-0992C636-5713-4E81-B9CA-FF21C8A57952Q33508911-CFBD1D7E-81C2-42CF-9075-B82A393B631DQ33535606-FAD99628-5CDC-4050-BDE0-673DD5CDF0CDQ33861680-511B044A-E5DC-4D3F-9B97-01789EEAD07DQ33927819-B8872995-3C2E-4AF3-B0EC-F750AEE2CA23Q33974696-34E119C2-3676-40BA-AE94-F38F6D4D62F5Q34076284-D3F1F00A-8518-4EA4-A80F-0C30407D2E60Q34110227-7174DD98-C479-46FB-8855-1A073CF99D91Q34302241-5061044D-E258-422A-A881-0A3688EB84B9Q34376138-9F4ADC18-BCF1-41CE-B9DD-F3A75E25EDEFQ34547897-B1F804D4-28AE-4E54-B52E-11EF7913383DQ34656871-490A5558-BCB4-4EA3-9964-6E2D12660E5DQ35171676-754A20F5-23E7-43C0-BA77-9EC182AF8F7EQ35596997-144094D8-EF3A-4348-9D21-7F3956783CCAQ35698081-BB0ECB38-DDC0-4159-B996-8EF69A1DEC36Q36259524-D35EEB1A-0A65-4ADE-8849-C96F820C59D6Q36320154-2ADADEEB-8D64-4C88-AA26-C5F990D022DEQ36676838-B81C9A8F-8F24-4C72-9470-0D227B5AFF53Q36764094-DBD2137B-BD05-4754-A0E8-BF6B77382D88Q37124928-036ED81F-70C3-4321-A9BE-1A6A50326C49Q37295252-C09C76AC-434F-401C-8CAE-C61D15754F10Q37416750-18D555FD-B8A4-43A0-BF1D-307D798F2793Q37513632-6D0E745E-0774-47FE-A1AF-FB0B2B9452BAQ37598633-88C96E13-E674-4B0A-AE34-9B1664B282FCQ37671455-C2EDCF90-B21A-4EC3-9852-543D6397649DQ37690932-2EFD32D0-6DB0-4567-822C-9639449E7E5F
P2860
Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@ast
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@en
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@nl
type
label
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@ast
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@en
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@nl
prefLabel
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@ast
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@en
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@nl
P2093
P3181
P356
P1476
Inhibitors of cathepsin B impr ...... the amyloid precursor protein
@en
P2093
Gregory Hook
Mark Kindy
Vivian Y H Hook
P304
P3181
P356
10.1074/JBC.M708362200
P407
P577
2008-03-21T00:00:00Z